# (Rac)-BRD0705

Cat. No.:	HY-116830A	1			
CAS No.:	1597440-03-3				
Molecular Formula:	$C_{20}H_{23}N_{3}O$				
Molecular Weight:	321.42				
Target:	GSK-3				
Pathway:	PI3K/Akt/mTOR; Stem Cell/Wnt				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

## SOLVENT & SOLUBILITY

Preparing Stock Solutions		Solvent Mass Concentration	1 mg	5 mg	10 mg			
	1 mM	3.1112 mL	15.5560 mL	31.1119 mL				
		5 mM	0.6222 mL	3.1112 mL	6.2224 mL			
		10 mM	0.3111 mL	1.5556 mL	3.1112 mL			
	Please refer to the so	lubility information to select the ap	propriate solvent.					
n Vivo		one by one: 10% DMSO >> 40% PE0 ng/mL (6.47 mM); Clear solution	G300 >> 5% Tween-8	0 >> 45% saline				
Solubility: ≥ 2.08 3. Add each solvent		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (6.47 mM); Clear solution						
	one by one: 10% DMSO >> 90% corn oil mg/mL (6.47 mM); Clear solution							

BIOLOGICAL ACTIV	ЛТҮ
Description	(Rac)-BRD0705 is a less active racemate of BRD0705. BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC <sub>50</sub> of 66 nM and a K <sub>d</sub> of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC <sub>50</sub> of 515 nM). BRD0705 can be used for acute myeloid leukemia (AML) <sup>[1][2]</sup> .

### REFERENCES

Н

ŅΗ

**Product** Data Sheet

// O



[1]. Wagner FF, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460.

[2]. Edward Scolnick, et al. Uses of paralog-selective inhibitors of gsk3 kinases. US20160375006A1.

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA